ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0571

Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study

Sabrina Hamroun1, Laure Gossec2, Serge Perrot3, Maxime Dougados4 and Anna Molto5, 1Cochin University Hospital, Paris, Ile-de-France, France, 2Sorbonne Université, Paris, France, 3Paris Dauphine University, Paris, France, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Groupe Hospitalier Cochin, AP-HP, Paris, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Disease Activity, gender, Patient reported outcomes, spondyloarthritis

Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared with men. The aim of this study was to evaluate the influence of gender on the tools used to assess disease activity in axial SpA, and their ability to discriminate Patient Acceptable Symptom State (PASS), depending on gender.

Methods: This is an ancillary analysis of the Predict-SpA cross-sectional study (NCT03039088). Patients had a diagnosis of axial SpA according to their rheumatologist and an indication to start a TNF inhibitor. Disease activity was assessed prior to initiation of treatment using BASDAI, ASDAS-CRP scores, patient and physician global assessment of disease activity. Patients were also asked to rate whether their health status in relation to axial SpA was considered acceptable or unacceptable (PASS, yes/no). To analyse the ability of disease activity assessment tools to discriminate PASS, we calculated a standardized mean difference (SMD) for each tool in the total population, in men and in women.

Results: Of the 526 patients included in Predict-SpA, 522 had an available PASS and were analysed, including 279 (53.4%) men and 243 (46.6%) women. Overall, women with a PASS had comparatively lower activity scores than men with a PASS. In the overall population, the BASDAI, ASDAS-CRP and patient global assessment of disease activity performed well in discriminating PASS (SMD 1.17, 0.93 and 1.36, respectively). However, there were gender differences, with BASDAI score performing better in women than in men (SMD 1.47 and 0.94, respectively). The physician global assessment was the least discriminating tool, with no gender differences (SMD 0.75, 0.80 and 0.81 in the overall population, in men and in women, respectively).

Conclusion: The disease activity assessment tools appear to be able to discriminate PASS, apart from the physician global assessment of disease activity, in the whole population. The ASDAS-CRP performs homogeneously according to gender, which argues in its favour at the population level. As the BASDAI has a better discriminating performance in women, it could be used in studies including only women.

Supporting image 1

Table 1. Performance of disease activity assessment tools in discriminating PASS in men and women with axial SpA.

Supporting image 2

Figure 1. Disease activity scores according to PASS in men and women with axial SpA.


Disclosures: S. Hamroun: None; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; S. Perrot: None; M. Dougados: AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6; A. Molto: AbbVie, 2, 5, MSD, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Hamroun S, Gossec L, Perrot S, Dougados M, Molto A. Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/gender-specific-performance-of-disease-activity-assessment-tools-in-axial-spondyloarthritis-ancillary-analysis-of-the-predict-spa-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gender-specific-performance-of-disease-activity-assessment-tools-in-axial-spondyloarthritis-ancillary-analysis-of-the-predict-spa-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology